Stock Market News
Dechra roars through first half of growth
Dechra reported strong trading in line with management expectations in its half-yearly report on Monday, with reported group revenue improving 11.2% year-on-year at constant exchange rates and 12.5% at actual exchange rates, to £194.1m.
The FTSE 250 company said European pharmaceuticals revenue growth was 5.8% at constant currencies, while North American pharmaceuticals revenue growth was 20.7%.
It saw underlying operating profit growth of 22.3% at constant exchange rates and 22.6% at actual exchange rates, with an operating margin expansion of 220 basis points to 24.6%.
The board said it saw "strong" cash conversion of 96.2%, which included pre-product launch stock builds.
Operating profit improved 22.3% to £47.4m and EBITDA was up 22% to £51m, both at constant exchange rates on an underlying basis.
During the period, a small bolt-on acquisition of RxVet in New Zealand was completed, with the major acquisition of AST Farma and Le Vet announced post period end.
Underlying diluted earnings per share grew 19.8% to 37.58p, the board highlighted, confirming the interim dividend would increase 20.0% to 7.33p.
"The group has delivered a strong performance during the period," said chief executive Ian Page.
"The board remains confident that we can continue to implement our strategy and meet our expectations for the current financial year, and deliver further growth in the future."
The FTSE 250 company said European pharmaceuticals revenue growth was 5.8% at constant currencies, while North American pharmaceuticals revenue growth was 20.7%.
It saw underlying operating profit growth of 22.3% at constant exchange rates and 22.6% at actual exchange rates, with an operating margin expansion of 220 basis points to 24.6%.
The board said it saw "strong" cash conversion of 96.2%, which included pre-product launch stock builds.
Operating profit improved 22.3% to £47.4m and EBITDA was up 22% to £51m, both at constant exchange rates on an underlying basis.
During the period, a small bolt-on acquisition of RxVet in New Zealand was completed, with the major acquisition of AST Farma and Le Vet announced post period end.
Underlying diluted earnings per share grew 19.8% to 37.58p, the board highlighted, confirming the interim dividend would increase 20.0% to 7.33p.
"The group has delivered a strong performance during the period," said chief executive Ian Page.
"The board remains confident that we can continue to implement our strategy and meet our expectations for the current financial year, and deliver further growth in the future."
Related share prices |
---|
Dechra Pharmaceuticals (DPH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price